On March 17, Jinhao medical (872925) recently released its 2020 annual report. During the reporting period, the company achieved operating revenue of 211480597.53 yuan, a year-on-year increase of 41.84%; the net profit attributable to shareholders of listed companies was 41388470.16 yuan, a year-on-year increase of 68.12%.
During the reporting period, the net cash flow from operating activities was 44544867.68 yuan, and the net assets belonging to shareholders of listed companies were 120778751.68 yuan by the end of 2020.
During the reporting period, the operating revenue was 211480600 yuan, an increase of 6, 2.3861 million yuan, an increase of 41.84%, mainly due to the company’s increased market investment, through participating in various domestic and international exhibitions, Alibaba international station and other channels to open up more ODM brand customers. With the brand customers’ increasing product popularity and market promotion investment, the demand of its downstream channels increases, and the corresponding customers’ purchasing scale from the company gradually expands.
During the reporting period, the amount of sales expenses was 20.2224 million yuan, an increase of 5.3875 million yuan or 36.32% over the same period last year, which was mainly due to the increase of 1.9758 million yuan in the salary of sales personnel due to the need of market development, the increase of sales personnel and the growth of performance; meanwhile, the company’s strengthening of market publicity led to an increase of 3.1588 million yuan in business publicity expenses in the current period
During the reporting period, the amount of financial expenses was 4.4136 million yuan, with a year-on-year increase of 4.9429 million yuan, which was mainly due to the exchange loss of 3.9127 million yuan caused by the fluctuation of foreign exchange rate
During the reporting period, the amount of investment income was 2.3553 million yuan, with a year-on-year increase of 2.3524 million yuan, an increase of 80%, Among them, the investment income of structured deposits and other financial products in the current period was 683400 yuan, an increase of 325100 yuan compared with the previous year, mainly due to the increase of accumulated investment in financial products in the current period compared with the same period of the previous year; the investment income of forward foreign exchange settlement and sales business was 1671900 yuan, an increase of 2027300 yuan compared with the same period of the previous year due to the continuous depreciation of the exchange rate of US dollar against RMB since the second half of 2020
According to digbei.com, Jinhao medical is mainly engaged in the R & D, production and sales of rehabilitation medical devices and household medical devices. Its main products include hearing aids, nebulizers, anti bedsore air cushion, etc.